Abstract: The present invention relates to a method of producing a chitin oligomer, including subjecting chitin-containing biomass to partial hydrolysis while pulverizing the chitin-containing biomass with a pulverization apparatus in the co-presence of water and an acid catalyst selected from phosphoric acid, nitrous acid, and an organic acid (Method 1); a method of producing N-acetylglucosamine, including hydrolyzing a chitin oligomer obtained by the Method 1 by adding water thereto, followed by heating (Method 2); and a method of producing a 1-O-alkyl-N-acetylglucosamine, including alcoholyzing a chitin oligomer by adding an alcohol thereto (Method 3).

Abstract: A composite material is formed by combining an expandable polymer having a charge with another polymer having an opposite charge to produce. In particular, the composite material can be prepared by combining the polymers with a medium such as and water, and expanding the mixture using a treatment that expands the mixture to produce, for example, insoluble porous foam-like composites.

Abstract: Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.

Abstract: Disclosed is synthesis of an O-Antigen oligosaccharide compound of Helicobacter pylori serotype O2, belonging to the field of organic synthesis. The disclosure obtains O-antigen disaccharide to tetracosasaccharide of Helicobacter pylori serotype O2 by chemical synthesis. A chemical synthesis method which is quite conducive to production of a glucose-?-lglucosidic bond is developed in the disclosure by a protectant strategy, temperature effect, solvent effect, and additive effect. The method is applied in synthesis of an O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm. A saccharide conjugate can be prepared from the synthesized O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm together with a carrier protein for immunology researches, playing an important role in preventing and treating Helicobacter pylori.

Abstract: Provided are a hyaluronic acid composition having excellent viscoelasticity and being easily injectable, and a preparation method thereof.

Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2?-fucosyllactose (2?FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.

Abstract: The present application discloses regioselectively substituted cellulose esters, films made from the regioselectively substituted cellulose esters and methods for making the same. The regioselectively substituted cellulose esters are synthesized using trifluoroacetic anhydride and cellulose with various acyl donors or acyl donor precursors.

Abstract: A compound that includes a dextran backbone having at least one C-type lectin targeting moieties attached thereto. Also disclosed are embodiments of the compound that include at least one therapeutic agent and/or at least one detection label attached to the dextran backbone. The compound may be effective for treatment of Corona Covid-19 (SARS-covid-2) virus, its variants and other related viral diseases, and disorders. Further disclosed are methods for diagnosing and treating diseases and/or disorders directly using the disclosed compounds.

Abstract: Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.

Abstract: The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.

Abstract: The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (?4?1) and alpha-V-beta-3 (? V?3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

Abstract: The present invention provides compositions and methods for the treatment of neurological disorders. In particular, the present invention can be used for treating and/or preventing the symptoms and/or comorbidities of neurodegenerative conditions, diseases or disorders, such as, for example, Alzheimer's and Parkinson's disease.

Abstract: An okra polygalacturonic acid having a uric acid-lowering effect, a method for preparing the same, and use of the same are disclosed. The method includes: smashing an okra, lixiviating the okra in ethanol, and filtering to obtain a filtrate and a residue; removing the filtrate, and lixiviating the residue in heated water to obtain an extraction solution; adding the ethanol into the extraction solution to precipitate okra crude polysaccharides; purifying the okra crude polysaccharides over an anion exchange column by eluting with water or a NaCl solution, a Tris-HCl solution or a NaCl-containing Tris-HCl solution, or a phosphate solution or a NaCl-containing phosphate solution, and collecting a fraction eluted by the NaCl solution, the NaCl-containing Tris-HCl solution, or the NaCl-containing phosphate solution; and concentrating, dialyzing and drying the fraction to obtain the okra polygalacturonic acid.

Abstract: The present invention includes methods of monitoring measurable residual disease in patients suffering from a proliferative disorder, determining which patients could benefit from treatment or intervention with crenolanib or salt in reducing residual disease and maintaining remission, and administering a therapeutically effective amount of crenolanib as a single agent or sequentially or concomitantly with another therapeutic agent.

Abstract: Methods and systems for the preparation of conditioned micronized active agents. Additionally, methods and systems for in-process conditioning of micronized active agent particles and compositions comprising conditioned micronized materials.

Abstract: Compounds described herein are mithramycin (MTM) oxide (OX) derivatives and MTM Hydrazine (HY) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.

Abstract: The present invention concerns a cellulose based composition for manufacturing a film or foil, which composition comprises at least one selected from the group consisting of cellulose acetate butyrate, cellulose acetate propionate and ethyl cellulose, together with tall oil fatty acid ester, as well as a manufacturing method thereof. The invention also concerns packaging film comprising the composition and use of the composition.

Abstract: A sulfated cellulose fiber having a cellulose I crystal structure is provided. A chemically modified cellulose fiber which has a cellulose I crystal and in which some hydroxyl groups of cellulose are substituted with a substituent represented by formula (1). An amount of the substituent introduced is 0.1 mmol to 3.0 mmol per 1 g of the chemically modified cellulose fiber, and an average degree of polymerization is 350 or more. (In formula (1), M represents a monovalent to trivalent cation.) In the production of the chemically modified cellulose fiber, a cellulose fiber is treated with sulfamic acid while maintaining a cellulose fiber shape to allow sulfamic acid and a cellulose fine fiber which is a constituent of the cellulose fiber to react with each other.

Abstract: Reversibly crosslinked, water-soluble cellulose ethers having at least two different ether components is disclosed. At least one ether component is an alkyl, hydroxyalkyl or carboxymethyl group and at least one is an alkyl group having an aldehyde function which forms hydrolyzable hemiacetals with free OH groups of the cellulose ether. The cellulose ethers are obtainable by selective oxidation of cellulose ethers containing alkyl groups having vicinal OH groups (glycol cleavage). Preferably, water-soluble cellulose ethers are co-etherified simultaneously or subsequently with 2,3-epoxypropanol (glycidol) or 3-chloro-1,2-propanediol and the 2,3-dihydroxypropyl ether groups converted entirely or partly into 2-oxoethyl ether groups by oxidation. Suitable oxidants include periodate, periodic acid or lead tetraacetate. After washing and drying, cellulose ethers reversibly crosslinked via hemiacetals can be dispersed in water or aqueous solutions, going into solution homogeneously with a time delay.